procedure. The success rate in growing long term cultures with renal carcinoma 
cells is 10-20% (24). Since approximately 40% of patients are HLA-A2 positive, 
a tumor vaccine produced from previously established HLA matched renal cell 
carcinoma cell lines could be widely used. Additionally, evidence is mounting 
that shared tumor antigens exist (23,24). HLA class I antigens are the restricting 
element for a cytotoxic T cell response. Allogeneic HLA-A2 matched tumor cells 
can induce cytotoxic T cell responses. The protocol will be restricted to patients 
who are HLA-A2-positive. 
2.8 Renal Carcinoma Cell Line 
Two cell lines, SK-RC-28 and SK-RC-39, will be used in combination for 
expression of IL-2. The combination will allow presentation of more renal 
associated antigens and allow greater allogenic stimulation. The cell line SK-RC- 
28 was derived from the 1979 primary nephrectomy specimen of a 51 year old 
woman with a solitary humeral metastasis. The parental cell line is a moderately 
well differentiated carcinoma that grows on soft agar but not in nude mice. The 
cell line SK-RC-39 was derived from the 1980 resection of local recurrence that 
occurred in a 55 year old woman five years after her primary nephrectomy. The 
parental line grows on soft agar and in nude mice; it has an in vitro doubling 
time of 42 hours. The antigenic phenotype of each cell line is shown below. 
cell line gpl60 gpl40 gpl20 URO-8 G250 HLA-A2 ABH/Rh 
SK-RC-28 + + - + + A+ 
SK-RC-39 - + + + - + 0 + 
Both cell lines have been infected with the retroviral vector NAP-AD/IL-2 (see 
appendix C for construction). The transfected cell lines constitutively secrete IL- 
2: SK-RC-28 secretes 20 U/ml and SK-RC-39 secretes 40 U/ml. These tumor 
cells will be irradiated with 10,000 rads prior to injection, to assure their 
inability to proliferate (see appendix E). Two dose levels of tumor cells will be 
used for the vaccines. 
2.9 Clinical Protocol 
This will be a pilot study of immunization with SK-RC-28 and SK-RC-39 
allogeneic tumor cells that have been altered to secrete IL-2, given to patients 
with renal cell carcinoma in order to test the safety of this procedure. Patients 
will be HLA tissue typed. Those who are HLA-A2 positive will receive 
vaccinations of allogenic HLA-A2 matched renal carcinoma cells that secrete IL- 
2. The expected accrual for this study is twelve patients. The expected duration 
for the trial will be twelve months. 
Recombinant DNA Research, Volume 15 
[923] 
